23rd week of 2015 patent applcation highlights part 20 |
Patent application number | Title | Published |
20150152090 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2015-06-04 |
20150152091 | CROP ENHANCEMENT - The invention relates to a method of crop enhancement. In particular, it relates to a method of enhancing crop plants by applying to the plants, plant parts, plant propagation material, or a plant growing locus, a compound of formula (I), and to the use of said compound for enhancing crops. | 2015-06-04 |
20150152092 | INHIBITORS OF Akt ACTIVITY - Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 2015-06-04 |
20150152093 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH - The invention is directed to a formula (I): | 2015-06-04 |
20150152094 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS - Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of dermal diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds. | 2015-06-04 |
20150152095 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL - The main purpose of the invention is to provide a novel aromatic heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include aromatic heterocyclic derivatives represented by general formula [1] and pharmaceutically acceptable salts thereof. | 2015-06-04 |
20150152096 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS - Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases. | 2015-06-04 |
20150152097 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein. | 2015-06-04 |
20150152098 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 - The present invention relates to an improved process for preparing (2R,3aR,10Z,11aS,12aR,14aR)-cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, ethyl ester. This compound is an intermediate in the overall synthesis route of the macrocyclic compound TMC 435. TMC 435 is an inhibitor of NS3/4A protease which plays an important role in the replication of the hepatitis C virus. | 2015-06-04 |
20150152099 | METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS - The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof. | 2015-06-04 |
20150152100 | SOLVATE FORM M OF TRAMETINIB DIMETHYL SULFOXIDE AND METHODS OF MAKING AND USING THEREOF - The present invention relates to a crystalline Form M of trametinib dimethyl sulfoxide solvate. Comparing with the prior art, Form M is a more stable crystalline form with better particle size distribution and good flowability and is non-hygroscopic. Therefore, it is more suitable for formulation. The present invention also relates to pharmaceutical compositions thereof, methods of making and using thereof. | 2015-06-04 |
20150152101 | ACTIVE COMPOUNDS FOR COMBATING GREASY SKIN - The present invention relates to the cosmetic use, as an agent for preventing and/or treating greasy skin or greasy-prone skin and/or an associated aesthetic skin disorder, of an effective amount of at least one compound represented by either of the general formulae (Ia) and (Ib). | 2015-06-04 |
20150152102 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE - A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group. | 2015-06-04 |
20150152103 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2015-06-04 |
20150152104 | 7-AZAINDOLE DERIVATIVES - Compounds of the formula (I) in which R, R | 2015-06-04 |
20150152105 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2015-06-04 |
20150152106 | SELECTIVE BROMINATION OF PERYLENE DIIMIDES AND DERIVATIVES THEREOF UNDER MILD CONDITIONS - The present invention is directed to novel process for the preparation of regioselective perylenediimides derivatives, specifically mono and dibrominated derivatives. | 2015-06-04 |
20150152107 | Novel Solid Forms of Phosphodiesterase Type 5 Inhibitors - The present invention relates to novel solid forms of phosphodiesterase type 5 (PDE5) inhibitors, especially to complex co-crystals, and to the solvates and/or the polymorphs of same. Said substances can be used to produce a pharmaceutical composition containing same as the useful active ingredient. Said compounds can exhibit a constant storage stability. | 2015-06-04 |
20150152108 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS - The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2015-06-04 |
20150152109 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS - The invention provides a compound of Formula (I) | 2015-06-04 |
20150152110 | STABLE COMPLEXES OF AN ALKALINE EARTH METAL SALT OF N5-METHYL-TETRAHYDROFOLIC ACID AND A POLYOL - Complexes between an alkaline earth metal salt of (6RS)- or (6S)-N | 2015-06-04 |
20150152111 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION - The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. | 2015-06-04 |
20150152112 | COMPOUNDS - The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases. | 2015-06-04 |
20150152113 | Positive Allosteric Modulators of MGLUR2 - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. Formula (I): | 2015-06-04 |
20150152114 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE - A process for the preparation of 4,6-dihalopyrimidin-5-amines of formula (II), or salts thereof, which comprises reacting 5-aminopyrimidin-4,6-diols of formula (III), or salts thereof, or a solvate either of the compound of formula (III) or of a salt thereof, with a halogenating agent, new intermediates useful in the preparation of the compound of formula (II) and processes for the preparation of these intermediates. The invention also refers to a process for the preparation of ticagrelor or a pharmaceutically acceptable salt thereof from 4,6-dihalo-2-(propylthio)pyrimidin-5-amine of formula (IIA). | 2015-06-04 |
20150152115 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2015-06-04 |
20150152116 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS - Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: | 2015-06-04 |
20150152117 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS - A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R | 2015-06-04 |
20150152118 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors - Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R | 2015-06-04 |
20150152119 | NICOTINIC RECEPTOR COMPOUNDS - Provided herein are compounds and methods of preparation of compounds that are capable of functioning as agonists or antagonists of a nicotinic receptor. Also provided are pharmaceutical compositions comprising one or more of these compounds, which may further comprise one or more additional therapeutic agents. Further provided are methods of treatment of various conditions that may be responsive to such activity at the nicotinic receptors, such as nicotine dependence. | 2015-06-04 |
20150152120 | METHODS FOR ONE-POT N-DEMETHYLATION/N-FUNCTIONALIZATION OF MORPHINE AND TROPANE ALKALOIDS - The present invention provides a method for the N-demethylation and N-functionalization of an N-methylated heterocycle such as a morphine alkaloid or tropane alkaloid. The method comprises reacting the heterocycle with an functionalization agent in the presence of a transition metal catalyst in air or in the presence of an oxidant. | 2015-06-04 |
20150152121 | Substituted Benzothienopyrimidines - The present invention relates to substituted benzothienopyrimidine compounds of general formula I: in which R | 2015-06-04 |
20150152122 | TYROSINASE INHIBITORS - The compositions and methods of described herein comprise novel ingredients effective to reduce unwanted pigmentation, such as skin discoloration, freckles, age spots, liver spots, sun damage, tans, pigmented acne marks, scars, pigmented birthmarks, hyperpigmentation, post-inflammatory hyperpigmentation, post-injury hyperpigmentation, melasma, cholasma, after-burn scar, nail stain, yellowing of skin, dark circles under eyes, and the like. The composition may include additional ingredients accordingly for a colored cosmetic, moisturizer, cleanser, toner, and the like. | 2015-06-04 |
20150152123 | Aluminum Metal Organic Framework Materials - The invention relates to monocrystalline single crystals of metal-organic framework materials comprising at least one aluminium metal ion, processes for preparing the same, methods for employing the same, and the use thereof. The invention also relates to monocrystalline aluminium metal-organic frameworks. | 2015-06-04 |
20150152124 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND - Provided is a surface treatment technique whereby excellent adhering function, excellent reacting function and rich diversity can be established. A surface treatment method that comprises applying a solution containing compound (α) to a substrate and thus providing compound (α) thereon, wherein: said compound (α) has at least an M-OH group and/or a group capable of forming M-OH (wherein M represents a metal atom), an amino group and a triazine ring; one or more said M-OH groups and/or groups capable of forming M-OH (wherein M represents a metal atom) are present; said amino group is bonded to a terminal; one or more said amino groups bonded to the terminal are present; and one or more said triazine rings are present. | 2015-06-04 |
20150152125 | SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF AS ANTI-TUMOR AGENTS - The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: (I) wherein A | 2015-06-04 |
20150152126 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS - The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions. | 2015-06-04 |
20150152127 | PERMEABLE GLYCOSIDASE INHIBITORS AND USES THEREOF - The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and/or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents. | 2015-06-04 |
20150152128 | NEW CARBAMATE GLYCOLIPID AND USE THEREOF - The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) | 2015-06-04 |
20150152129 | Synthetic Oligosaccharides for P. Aeruginosa Vaccine - The present invention provides synthetic | 2015-06-04 |
20150152130 | TRANS-RESVERATROL POLYSACCHARIDE, METHOD FOR PRODUCING THE SAME, AND COMPOSITION COMPRISING THE SAME - An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. Another object of the present invention is to provide a trans-resveratrol derivative that has no toxicity against cells and has sufficient antioxidative properties and/or a sufficient whitening effect. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of γ-cyclodextrin glucanotransferase. | 2015-06-04 |
20150152131 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO- -D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THE SAME - A compound represented by a formula [1D] as shown below (wherein R | 2015-06-04 |
20150152132 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same - A compound represented by the general formula (III) which serves as an intermediate of an oligonucleotide analog having stable and excellent antisense or antigene activity or having excellent activity as a detection reagent (probe) for a specific gene or as a primer for the initiation of amplification of a specific gene can be produced at high yields regardless of the type of nucleobase by a method comprising reacting a compound represented by the general formula (II) or a salt thereof with a trimethylsilylated compound obtained from a compound represented by the general formula (IVb), wherein X, Y, Z, A, R, and B are as defined in claim | 2015-06-04 |
20150152133 | ACYLATION DERIVATIVES OF PARIDIS SAPONINS I, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and relates to novel Polyphyllin I derivatives of formula (I) that is acylated at the 5′-position of arabinofuranosyl or a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. | 2015-06-04 |
20150152134 | PROTEIN RETROSPLICING ENABLED BY A DOUBLE LIGATION REACTION - Proteins containing a C-terminal thioester are important intermediates in semi-synthesis. Currently there is one main method for the synthesis of protein thioesters that relies upon the use of engineered inteins. The invention involves, in some aspects a method, utilizing Sortase A, for preparation of recombinant proteins containing a C-terminal | 2015-06-04 |
20150152135 | Method for Fractionally Extracting Mucin and Collagen - Provided is a method for fractionally extracting mucin and collagen from a jellyfish as a single raw material, including: (A) a protein-separating process including breaking a jellyfish to provide broken pieces containing water; subjecting the pieces to first solid-liquid separation to provide a liquid component; mixing the liquid component with a water-soluble alcohol having 1-4 carbons to prepare a first mixture wherein a concentration of the alcohol in the first mixture is at least 50 vol %; and subjecting the first mixture to second solid-liquid separation to provide solids, and (B) a fractionating process including mixing the solids with an aqueous solution of a water-soluble alcohol having 1-4 carbons wherein a concentration of the alcohol in the solution is from 10-40 mass %, to provide a second mixture; and subjecting the second mixture to third solid-liquid separation whereby the mixture is divided into a mucin-containing liquid constituent and a collagen-containing solid constituent. | 2015-06-04 |
20150152136 | MEMBRANE WITH SURFACE CHANNELS - Membranes having parallel channels in a surface of the membranes, wherein the channels have side walls having rough surfaces; filters and devices including at least one membrane, and methods of making and using the membranes, are disclosed. | 2015-06-04 |
20150152137 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES - The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions. | 2015-06-04 |
20150152139 | Peptide Tyrosinase Activators - Peptides that increase melanin synthesis are provided. These peptides include pentapeptides YSSWY, YRSRK, and their variants. The peptides may activate the enzymatic activity of tyrosinase to increase melanin synthesis. The pharmaceutical, cosmetic, and other compositions including the peptides are also provided. The methods of increasing melanin production in epidermis of a subject are provided where the methods include administering compositions comprising an amount of one or more peptides effective to increase the melanin production. The methods also include treating vitiligo or other hypopigmentation disorders with compositions including one or more peptides. | 2015-06-04 |
20150152140 | PEPTIDES DERIVED FROM VIRAL PROTEINS FOR USE AS IMMUNOGENS AND DOSAGE REACTANTS - The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, HPV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis. | 2015-06-04 |
20150152141 | CYTOKINE - A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described. | 2015-06-04 |
20150152142 | MODIFIED VIRUS VECTORS AND METHODS OF MAKING AND USING THE SAME - The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo. | 2015-06-04 |
20150152143 | Flagellin Fusion Proteins - Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion. | 2015-06-04 |
20150152144 | SALMONELLA TYPHI TY21A EXPRESSING YERSINIA PESTIS F1-V FUSION PROTEIN AND USES THEREOF - Described herein is the generation of a plasmid construct for expression of a | 2015-06-04 |
20150152145 | RECOMBINANT STRAIN OF MYCOBACTERIUM BOVIS BACILLUS CALMETTE-GUERIN (BCG), IMMUNOGENIC COMPOSITION AND USE - The present invention relates to recombinant | 2015-06-04 |
20150152146 | NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED WITH PLANTS AND USES THEREOF FOR PLANT IMPROVEMENT - Recombinant polynucleotides and recombinant polypeptides useful for improvement of plants are provided. The disclosed recombinant polynucleotides and recombinant polypeptides find use in production of transgenic plants to produce plants having improved properties. | 2015-06-04 |
20150152147 | SERUM ALBUMIN BINDING MOLECULES - The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain ( | 2015-06-04 |
20150152148 | HYPOALLERGENIC HYBRID PROTEINS OF MAJOR GROUP 1 AND 2 MITE ALLERGENS FOR USE IN THE TREATMENT OF ALLERGIES - The present invention refers to recombinant AND molecules coding to hybrids polypeptides of different allergens from | 2015-06-04 |
20150152149 | Peptides Having Activity of Inhibiting Infections of Respiratory Viruses and Use of the Same - Peptides having activity of inhibiting infections of respiratory viruses and use of the same are disclosed. The peptides can be synthesized by chemical or genetic engineering methods, and they have functional domain capable of binding to surface glycoprotein of respiratory viruses and activity of inhibiting infections of respiratory viruses. The peptides are useful for blocking infections of respiratory viruses in target cells, for prevention/treatment of said infections, and for development of new prophylactic/therapeutic medicaments against respiratory viruses. Also disclosed are a kit for screening peptide capable of inhibiting said infections and the screening method. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum antiviral activities. | 2015-06-04 |
20150152150 | Selective PYY compounds and uses thereof - The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds. | 2015-06-04 |
20150152151 | Controlled Gene Expression Methods - Methods and compositions for controlling gene expression are disclosed. | 2015-06-04 |
20150152152 | MUC-1 CYTOPLASMIC DOMAIN PEPTIDES AS INHIBITORS OF CANCER - Peptides from the Mucin 1 (MUC1) cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo. | 2015-06-04 |
20150152153 | METHOD - The present invention relates to a method of producing keratin hydrolysate comprising the steps of: i) reacting keratin material with a protease; and ii) reacting keratin material with a chemical oxidant; wherein step ii occurs: a) after step i); b) during step i) when the selected protease hydrolyses under the pH conditions used for the chemical reaction and/or c) prior to step i) when the selected protease hydrolyses under the reaction conditions used for the chemical reaction; keratin hydrolysate so produced and uses thereof. | 2015-06-04 |
20150152154 | TUMOR VACCINATION INVOLVING A HUMORAL IMMUNE RESPONSE AGAINST SELF-PROTEINS - The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject. | 2015-06-04 |
20150152155 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME - A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. | 2015-06-04 |
20150152156 | TISSUE PROTECTIVE PEPTIDES AND USES THEREOF - The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor. The invention is further directed to the consensus sequences for use in engineering a synthetic tissue protective peptide. These tissue protective peptides also include fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO. The invention further encompasses methods for treating or preventing a disease or disorder using tissue protective peptides of the current invention. The invention also encompasses methods for enhancing excitable tissue function using tissue protective peptides of the current invention. | 2015-06-04 |
20150152157 | Double-Acylated GLP-1 Derivatives - The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first K residue and a second K residue, at positions corresponding to position 26, and 34, respectively, of GLP-1(7-37) (SEQ ID NO:1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is Chem. 2: HOOC—C | 2015-06-04 |
20150152158 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce β cell regeneration. | 2015-06-04 |
20150152159 | MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES - Modified bovine somatotropin polypeptides and uses thereof are provided. | 2015-06-04 |
20150152160 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided. | 2015-06-04 |
20150152161 | FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME - This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human β-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain of a human MHC class I molecule, (vi) a third peptide linker, (vii) a variable region from a heavy chain of a scFv fragment of an antibody, and (viii) a variable region from a light chain of such scFv fragment, wherein the consecutive amino acids which correspond to (vii) and (viii) are bound together directly by a peptide bond or by consecutive amino acids which correspond to a fourth peptide linker, wherein the antibody from which the scFv fragment is derived specifically binds to mesothelin. | 2015-06-04 |
20150152162 | ALBUMIN-PURIFICATION METHOD COMPRISING A NANOFILTRATION STEP, SOLUTION, AND COMPOSITION FOR THERAPEUTIC USE CONTAINING THE SAME - The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not lass than 7, to nanofiltration in a temperature range of between 15 DEG C and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use. | 2015-06-04 |
20150152163 | PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING SAME - An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with β-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method. | 2015-06-04 |
20150152164 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF - The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods. | 2015-06-04 |
20150152165 | MATRIX METALLOPROTEINASE CLEAVABLE PROTEIN POLYMERS FOR CANCER GENE THERAPY - A delivery system that includes a recombinantly synthesized protein polymer with protease cleavage sites such as matrix metalloproteinase responsive sequences engineered within the protein polymer. The system may be used to treat cancer, wounds, or pathological conditions in other tissues that express excess protease relative to healthy tissue. | 2015-06-04 |
20150152166 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CYTOMEGALOVIRUS - The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection. | 2015-06-04 |
20150152167 | HIV-1-NEUTRALIZING ANTIBODY POTENCY AND BREADTH VIA CELL RECEPTOR ANCHORING USING BISPECIFIC ANTIBODIES WITH NATIVE ARCHITECTURE - In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV. | 2015-06-04 |
20150152168 | HIGH-AFFINITY MONOCLONAL ANTIBODIES FOR BOTULINUM TOXIN TYPE B - High affinity antibodies for binding epitopes of BoNT/B and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/B in a sample. | 2015-06-04 |
20150152169 | Inhibitors of thioredoxin-interacting protein (TXNIP) for therapy - Described is a compound capable of reducing or inhibiting (a) the biological activity of thioredoxin-interacting protein (TXNIP) or (b) the expression of the gene encoding TXNIP for treating a condition where improving the resistance towards oxidative stress has a beneficial effect, e.g., for improving female fertiliy or extending healthy lifespan. | 2015-06-04 |
20150152170 | METHODS FOR INCREASING MUSCLE CONTRACTILITY - The present disclosure provides methods for increasing muscle contractility in a myotubular myopathy subject following administration of fewer than 20 doses of a chimeric polypeptide that has a myotubularin protein and an internalizing moiety. | 2015-06-04 |
20150152171 | Modulation of TLR4-Signaling Pathway - The present invention relates to compounds for use in modulating the toll-like receptor 4 (TLR4) signaling pathway, as well as to a pharmaceutical composition comprising said compounds. | 2015-06-04 |
20150152172 | COMPOSITIONS AND METHODS FOR BINDING CYSTEINYL LEUKOTRIENES (CYSLTS) FOR TREATMENT OF DISEASE - Methods are provided for using antibodies that bind one or more cysteinyl leukotrienes (cysLTs) for treatment of diseases, including inflammatory diseases and asthma, associated with aberrant levels of one or more cysLTs. Anti-cysLT antibodies and antigen-binding antibody fragments, and compositions containing such antibodies and antibody fragments, are also provided. | 2015-06-04 |
20150152173 | COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASE - The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage. | 2015-06-04 |
20150152174 | CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A IN COMPLEX WITH FIBRINOGEN DERIVED PEPTIDE AND USES THEREOF - The present invention discloses crystal structure of | 2015-06-04 |
20150152175 | THERAPIES FOR CANCER USING RLIP76 - The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region. | 2015-06-04 |
20150152176 | ANTAGONIST ANTIBODIES AGAINST GDF-8 - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 2015-06-04 |
20150152177 | High Affinity Human Antibodies to Human Angiopoietin-2 - The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis. | 2015-06-04 |
20150152178 | IL-17 Antagonistic Antibodies - An IL-17 binding molecule, in particular .an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions or the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis. | 2015-06-04 |
20150152179 | ANTIBODIES WITH DECREASED DEAMIDATION PROFILES - The present invention relates to antibodies with decreased deamidation profiles, and methods for producing antibodies with decreased deamidation profiles. | 2015-06-04 |
20150152180 | PD-1 SPECIFIC ANTIBODIES AND USES THEREOF - One aspect of the present disclosure provides antibodies that can act as agonists of PD-1, thereby modulating immune responses regulated by PD-1. Another aspect of the disclosure provides compositions comprising PD-1 specific antibodies and their use in methods of down regulating the immune response. These methods can be practiced on any subject, including humans or animals. Anti-PD-1 antibodies disclosed herein may be used, in another aspect of the invention to detect PD-1 or its fragments in a biological sample. The amount of PD-1 detected may be correlated with the expression level of PD-1, and associated with the activation status of immune cells (e.g., activated T cells, B cells, and/or monocytes) in the subject. | 2015-06-04 |
20150152181 | ANTI-B7-H6 ANTIBODY, FUSION PROTEINS, AND METHODS OF USING THE SAME - Antibodies, chimeric antigen receptors, and bispecific T-cell engagers having specificity for B7-H6 and methods for using the same in the diagnosis and treatment of disorders associated with B7-H6 expression are provided. | 2015-06-04 |
20150152182 | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION - A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation. | 2015-06-04 |
20150152183 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. | 2015-06-04 |
20150152184 | METHODS RELATED TO PANITUMUMAB - The present invention relates to the characterization and production of panitumumab. | 2015-06-04 |
20150152185 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 2015-06-04 |
20150152186 | SITE-SPECIFIC ANTIBODY-MEDIATED ACTIVATION OF PROAPOPTOTIC CYTOKINES: AMAIZe (ANTIBODY-MEDIATED APOPTOSIS INDUCING CYTOKINES) - Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity. | 2015-06-04 |
20150152187 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides - This invention relates to anti-prostate-specific membrane antigen antibodies (αPSMA) and αPSMA antibody—nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid. | 2015-06-04 |
20150152188 | AN IL-15 AND IL-15R\alpha SUSHI DOMAIN BASED IMMUNOCYTOKINES - The immunocytokine includes (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to the conjugate, wherein the conjugate includes (i) a polypeptide including the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide including the amino acid sequence. | 2015-06-04 |
20150152189 | MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP) | 2015-06-04 |
20150152190 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates - This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses. | 2015-06-04 |